These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

332 related items for PubMed ID: 31887730

  • 1. Meta-Analysis of the Diagnostic Accuracy of Primary Bone and Soft Tissue Sarcomas by 18F-FDG-PET.
    Younis MH, Abu-Hijleh HA, Aldahamsheh OO, Abualruz A, Thalib L.
    Med Princ Pract; 2020; 29(5):465-472. PubMed ID: 31887730
    [Abstract] [Full Text] [Related]

  • 2. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis.
    Bastiaannet E, Groen H, Jager PL, Cobben DC, van der Graaf WT, Vaalburg W, Hoekstra HJ.
    Cancer Treat Rev; 2004 Feb; 30(1):83-101. PubMed ID: 14766127
    [Abstract] [Full Text] [Related]

  • 3. Differentiation of soft tissue and bone sarcomas from benign lesions utilizing 18F-FDG PET/CT-derived parameters.
    Chen B, Feng H, Xie J, Li C, Zhang Y, Wang S.
    BMC Med Imaging; 2020 Jul 25; 20(1):85. PubMed ID: 32711449
    [Abstract] [Full Text] [Related]

  • 4. Texture analysis on (18)F-FDG PET/CT images to differentiate malignant and benign bone and soft-tissue lesions.
    Xu R, Kido S, Suga K, Hirano Y, Tachibana R, Muramatsu K, Chagawa K, Tanaka S.
    Ann Nucl Med; 2014 Nov 25; 28(9):926-35. PubMed ID: 25107363
    [Abstract] [Full Text] [Related]

  • 5. Dual-time point 18FDG-PET/CT imaging may be useful in assessing local recurrent disease in high grade bone and soft tissue sarcoma.
    Dancheva Z, Bochev P, Chaushev B, Yordanova T, Klisarova A.
    Nucl Med Rev Cent East Eur; 2016 Nov 25; 19(1):22-7. PubMed ID: 26841376
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Value of FDG PET/CT in Patient Management and Outcome of Skeletal and Soft Tissue Sarcomas.
    Sheikhbahaei S, Marcus C, Hafezi-Nejad N, Taghipour M, Subramaniam RM.
    PET Clin; 2015 Jul 25; 10(3):375-93. PubMed ID: 26099673
    [Abstract] [Full Text] [Related]

  • 8. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors.
    Shin DS, Shon OJ, Han DS, Choi JH, Chun KA, Cho IH.
    Ann Nucl Med; 2008 Aug 25; 22(7):603-9. PubMed ID: 18756363
    [Abstract] [Full Text] [Related]

  • 9. Utility of positron emission tomography/computed tomography (PET/CT) imaging in the evaluation of sarcomas: A systematic review.
    Lim HJ, Johnny Ong CA, Tan JW, Ching Teo MC.
    Crit Rev Oncol Hematol; 2019 Nov 25; 143():1-13. PubMed ID: 31449981
    [Abstract] [Full Text] [Related]

  • 10. Is there a need for dedicated bone imaging in addition to 18F-FDG PET/CT imaging in pediatric sarcoma patients?
    Walter F, Czernin J, Hall T, Allen-Auerbach M, Walter MA, Dunkelmann S, Federman N.
    J Pediatr Hematol Oncol; 2012 Mar 25; 34(2):131-6. PubMed ID: 22134608
    [Abstract] [Full Text] [Related]

  • 11. Volume-Based F-18 FDG PET/CT Imaging Markers Provide Supplemental Prognostic Information to Histologic Grading in Patients With High-Grade Bone or Soft Tissue Sarcoma.
    Andersen KF, Fuglo HM, Rasmussen SH, Petersen MM, Loft A.
    Medicine (Baltimore); 2015 Dec 25; 94(51):e2319. PubMed ID: 26705220
    [Abstract] [Full Text] [Related]

  • 12. Clinical value of [18-F]] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas.
    Schwarzbach MH, Dimitrakopoulou-Strauss A, Willeke F, Hinz U, Strauss LG, Zhang YM, Mechtersheimer G, Attigah N, Lehnert T, Herfarth C.
    Ann Surg; 2000 Mar 25; 231(3):380-6. PubMed ID: 10714631
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparison of 18F-FDG PET/CT with bone scintigraphy for detection of bone metastasis: a meta-analysis.
    Cheng X, Li Y, Xu Z, Bao L, Li D, Wang J.
    Acta Radiol; 2011 Sep 01; 52(7):779-87. PubMed ID: 21712464
    [Abstract] [Full Text] [Related]

  • 17. [18F-FDG-PET-CT in soft tissue sarcomas: when to image?].
    Rodríguez-Alfonso B, Mucientes Rasilla J, Mitjavila Casanovas M, Cardona Arboniés J, Cubedo R.
    Rev Esp Med Nucl Imagen Mol; 2014 Sep 01; 33(1):43-9. PubMed ID: 24094372
    [No Abstract] [Full Text] [Related]

  • 18. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Sep 01; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 19. Monitoring bone and soft-tissue tumors after carbon-ion radiotherapy using ¹⁸F-FDG positron emission tomography: a retrospective cohort study.
    Yanagawa T, Saito K, Kiyohara H, Ohno T, Nakano T, Takagishi K.
    Radiat Oncol; 2015 Dec 21; 10():259. PubMed ID: 26691334
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and Limitations of F-18-fluoro-2-deoxy-D-glucose Positron Emission Tomography to Differentiate Between Malignant and Benign Bone and Soft Tissue Tumors.
    Miwa S, Mochizuki T, Yamamoto N, Shirai T, Hayashi K, Takeuchi A, Inatani H, Igarashi K, Higuchi T, Abe K, Taniguchi Y, Aiba H, Ikeda H, Tsuchiya H.
    Anticancer Res; 2018 Jul 21; 38(7):4065-4072. PubMed ID: 29970532
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.